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Abstract
 
We report the efficient identification of four human histocompatibility leukocyte antigen
 
(HLA)-A
 
*
 
0201–presented cytotoxic T lymphocyte (CTL) epitopes in the tumor-associated
antigen PRAME using an improved “reverse immunology” strategy. Next to motif-based
HLA-A
 
*
 
0201 binding prediction and actual binding and stability assays, analysis of in vitro
proteasome-mediated digestions of polypeptides encompassing candidate epitopes was incor-
porated in the epitope prediction procedure. Proteasome cleavage pattern analysis, in particular
determination of correct COOH-terminal cleavage of the putative epitope, allows a far more
accurate and selective prediction of CTL epitopes. Only 4 of 19 high affinity HLA-A
 
*
 
0201
binding peptides (21%) were found to be efficiently generated by the proteasome in vitro. This
approach avoids laborious CTL response inductions against high affinity binding peptides that
are not processed and limits the number of peptides to be assayed for binding. CTL clones
induced against the four identified epitopes (VLDGLDVLL, PRA
 
100–108
 
; SLYSFPEPEA,
PRA
 
142–151
 
; ALYVDSLFFL, PRA
 
300–309
 
; and SLLQHLIGL, PRA
 
425–433
 
) lysed melanoma, renal
cell carcinoma, lung carcinoma, and mammary carcinoma cell lines expressing PRAME and
HLA-A
 
*
 
0201. This indicates that these epitopes are expressed on cancer cells of diverse histo-
logic origin, making them attractive targets for immunotherapy of cancer.
 
Key words: antigen presentation • antigen processing • cytotoxic T lymphocyte induction • 
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Introduction
 
T cell–based immunotherapy of cancer has been successful
in numerous mouse tumor model systems (1) and so far ef-
ficacious in a limited number of clinical conditions (2–6).
Specific T cell–mediated immunotherapy requires the
identification of tumor-specific antigens carrying T cell
epitopes presented in the context of HLA class I and/or
HLA class II molecules (for reviews, see references 1 and
7–9). The strategy, pioneered by Boon and coworkers, of
screening melanoma cDNA libraries with CTLs derived
from tumor infiltrating lymphocytes, has been successful in
 
the identification of CTL epitopes in unknown tumor-
associated proteins. The MAGE, BAGE, and GAGE fami-
lies of tumor-associated testis-specific antigens (10–13), as
well as the melanocyte differentiation antigens overex-
pressed in tumors like tyrosinase, Melan-A/MART-1, and
gp100 (14–17) have been identified in this manner. This
strategy requires the availability of CTL clones from mixed
leukocyte tumor cultures of cancer patients. Consequently,
any CTL epitope that is not successful in activating CTLs
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that can be expanded in vitro (e.g., subdominant epitopes)
will be missed. For the systematic detection of CTL
epitopes presented in a broad range of HLA class I mole-
cules, there is a great need for an efficient strategy. The
strategy of predicting potential CTL epitopes in already
identified tumor-associated proteins followed by in vitro
sensitization of CTLs against these putative epitopes (also
designated “reverse immunology”) has the advantage that it
does not utilize patient-derived T cells as a primary screen
and therefore allows a more systematic search for new CTL
epitopes. Reverse immunology has been used to identify
new CTL epitopes in MAGE-1 (18), MAGE-2 (19),
MAGE-3 (20–23), TRP2 (24), gp100 (25), and HER-2/
neu (19). However, so far this strategy has been rather inef-
ficient, mainly because CTLs raised against putative epitopes
were often unable to recognize tumor cells expressing the
source protein (26–30). Explanations for these failures are both
an insufficient affinity of the induced CTLs for their MHC–
peptide complex but more often the lack of processing of the
presumed epitope (9). Recently, Chaux et al. successfully ap-
plied an alternative strategy of in vitro CTL inductions against
dendritic cells (DCs)
 
1
 
 transduced with MAGE-1, abandoning
the strategy of epitope prediction and allowing processing of
the relevant epitopes to take place by the APC (31).
In this study, we chose to improve the epitope predic-
tion strategy by verifying the proteasome-mediated genera-
tion of peptides in order to identify HLA-A
 
*
 
0201–pre-
sented CTL epitopes in the so-called PRAME protein. The
main intracellular mechanisms that define the exact amino
acid (aa) sequence of a CTL epitope include enzymatic
breakdown of the protein by the proteasome, transporter-
associated with antigen processing (TAP)-mediated translo-
cation into the endoplasmic reticulum (ER) and binding of
the peptide with sufficient affinity in the groove of an
MHC class I molecule (for reviews, see references 32 and
33). The COOH terminus of CTL epitopes requires exact
cleavage by the proteasome (34–37), whereas NH
 
2
 
-termi-
nal extensions of the epitope can apparently be trimmed by
putative aminopeptidase activity mainly in the ER (36, 38–
41) or in the cytosol (34, 42). In vitro proteasome-mediated
digestions are known to reliably yield MHC class I ligands
from viral and model protein-derived polypeptides (43–47).
Therefore, after identification of HLA-A
 
*
 
0201 binding
peptides, we now incorporated in vitro proteasome-medi-
ated digestions of 27-mer polypeptides encompassing high
affinity binding peptides in the epitope prediction proce-
dure. Digestion pattern analysis permitted assessment of ef-
ficient COOH-terminal generation of putative epitopes
and, in addition, enabled evaluation of possible premature
destruction by major cleavage sites within the epitope, as
observed by us in a variant viral sequence (47).
 
The tumor-associated PRAME protein (48) is a particu-
larly attractive target of T cell–based immunotherapy of
cancer because of its expression in a wide variety of tu-
mors, including melanoma (95% of patients), renal cell
cancer (41%), lung cancer (50%), mammary cancer (27%),
acute leukemias (30%), and multiple myeloma (52%; refer-
ences 49–51), and because of its absence from normal tis-
sues, except testis, and its very low levels in endometrium,
ovaries and adrenals. We focussed on HLA-A
 
*
 
0201 as a re-
striction element because of its high prevalence (45.8%)
among the Caucasian population (52). Via the improved
multistep epitope prediction procedure, we report here the
identification of four naturally processed HLA-A
 
*
 
0201–
presented CTL epitopes in PRAME that are recognized by
CTLs on cell lines derived from tumors of various histo-
logic origins. This study underscores the importance of in-
corporating processing criteria for accurate identification of
CTL epitopes.
 
Materials and Methods
 
Cell Lines and Culture Conditions.
 
The EBV-transformed B
lymphoblastoid cell line (B-LCL) JY was cultured in complete
culture medium consisting of IMDM (BioWhittaker) supple-
mented with 8% FCS (Greiner), 100 IU/ml penicillin, and 2 mM
 
l
 
-glutamine. The processing-defective T2 cell line was a gift from
Dr. P. Cresswell (Yale University, New Haven, CT). Melanoma
cell lines (Mel603, M453, and FM3), renal cell carcinoma cell
lines (MZ1851, MZ1774, and MZ1257), and mammary carci-
noma cell line MCF7 were provided by Dr. P. Schrier (Leiden
University Medical Center). Mammary carcinoma cell line ZR-
75-1 was obtained from the American Type Culture Collection.
Lung carcinoma cell lines GLC02 and GLC36 were provided by
Dr. L. de Leij (University of Groningen, Groningen, The Neth-
erlands). The CD40 ligand–transfected mouse L cell line (53) that
was used for generation of activated B cells was donated by Dr. C.
van Kooten (Leiden University Medical Center). PRAME cDNA
was provided by Dr. P. Coulie (Ludwig Institute for Cancer Re-
search, Brussels, Belgium). The PRAME-encoding insert was
cloned into vector pDR2 (Invitrogen), conferring hygromycine
resistance. The renal cell carcinoma cell line MZ1851 was trans-
fected with pDR2-PRAME using Fugene (Boehringer) as trans-
fection reagent. After 48 h, hygromycine (100 
 
m
 
g/ml) was added
to select transfected cells. Hygromycine-resistant cells were tested
by reverse transcription (RT)-PCR for PRAME expression.
 
Peptides.
 
Peptides were synthesized by solid phase strategies
on an automated multiple peptide synthesizer (Abimed AMS 422)
using 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry. Short
peptides for CTL inductions were dissolved in 20 
 
m
 
l DMSO, di-
luted in 0.9% NaCl to a peptide concentration of 1 mg/ml, and
stored at 
 
2
 
20
 
8
 
C before usage. The fluorescein (FL)-labeled refer-
ence peptide as used in the competition-based HLA-A
 
*
 
0201
binding assay was synthesized, labeled, and characterized as de-
scribed earlier (54). The sequence of the FL-labeled peptide was
FLPSDYFPSV (hepatitis B virus [HBV] nucleocapsid 18–27; ref-
erence 55) wherein we substituted the tyrosine with a cysteine to
tag an FL group to the peptide: FLPSDC(FL)FPSV (54). The 27-
mer polypeptides used for in vitro proteasome digestion were syn-
thesized as described above, purified by reversed phase-HPLC in
an acetonitrile–water gradient and lyophilized from acetonitrile–
water overnight. Purity was confirmed by mass spectrometry.
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid; B-LCL, B lymphoblastoid
cell line; DC, dendritic cell; ER, endoplasmic reticulum; FI, fluorescence
index; FL, fluorescein; HBV, hepatitis B virus; MS, mass spectrometry;
RT, reverse transcription; TAP, transporter-associated with antigen pro-
cessing. 
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Cellular Competition–based HLA-A
 
*
 
0201 Peptide Binding As-
say.
 
The affinity of peptides for HLA-A
 
*
 
0201 was analyzed us-
ing the homozygous HLA-A
 
*
 
0201
 
1
 
 B-LCL JY as described pre-
viously (54), with minor adaptations. In brief, naturally bound
peptides were stripped from the HLA-A
 
*
 
0201 molecules by ex-
posing the JY cells for 90 s to ice-cold citric acid buffer with pH
3.1 (1:1 mixture of 0.263 M citric acid and 0.123 M Na
 
2
 
HPO
 
4
 
).
Cells were immediately buffered with ice-cold IMDM contain-
ing 2% FCS, washed twice in the same medium, and resuspended
in 2% FCS/IMDM containing 2 
 
m
 
g/ml human 
 
b
 
2
 
-microglublin
(Sigma-Aldrich). Subsequently, the stripped JY cells were plated
at 4 
 
3
 
 10
 
4
 
/well
 
 
 
in a 96-well V-bottomed plate together with 150
nM of a known high affinity HLA-A2
 
*
 
0201 binding FL-labeled
reference peptide (55) and titrated concentrations of competitor
test peptide. After incubation for 24 h at 4
 
8
 
C, cells were washed
three times in PBS containing 1% BSA, fixed with 0.5%
paraformaldehyde, and analyzed on a FACScan™ flow cytometer
(Becton Dickinson). The percentage inhibition of FL-labeled ref-
erence peptide binding was calculated using the following for-
mula: [1 
 
2 
 
(MF
 
reference and competitor peptide
 
 
 
2
 
 MF
 
no reference peptide
 
)/
(MF
 
reference peptide
 
 
 
2
 
 MF
 
no reference peptide
 
)] 
 
3
 
 100%. The binding af-
finity of competitor peptide is expressed as the concentration
needed to inhibit 50% binding of the FL-labeled reference pep-
tide (IC
 
50
 
). An IC
 
50
 
 
 
#
 
 5 
 
m
 
M was considered high affinity bind-
ing, 5 
 
m
 
M 
 
,
 
 IC
 
50
 
 
 
#
 
 15 
 
m
 
M was considered intermediate affinity
binding, 15 
 
m
 
M 
 
,
 
 IC
 
50
 
 
 
#
 
 100 
 
m
 
M was judged low affinity bind-
ing, and IC
 
50
 
 
 
.
 
 100 
 
m
 
M was considered not binding.
 
Peptide–MHC Complex Dissociation Assay.
 
Binding stability at
37
 
8
 
C of peptides complexed with HLA-A
 
*
 
0201 was measured as
described previously (56). In short, JY cells were treated with
10
 
2
 
4
 
 M emetine (Sigma-Aldrich) for 1 h at 37
 
8
 
C to stop de novo
synthesis of MHC class I molecules. Subsequently, endogenous
bound peptides in HLA-A
 
*
 
0201 were removed by mild acid
treatment (see above) and reconstituted with the peptide of inter-
est at 200 
 
m
 
M in 2% FCS/IMDM containing 2 
 
m
 
g/ml human
 
b
 
2
 
-microglublin (Sigma-Aldrich) for 1.5 h at room temperature.
Hereafter, cells were washed twice to remove free peptide and
incubated at 37
 
8
 
C for 0, 2, 4, and 6 h. Subsequently, expressed
HLA-A
 
*
 
0201–peptide complexes on JY cells were stained using
the conformation-specific Moab BB7.2 and goat anti–mouse
IgG–FITC and analyzed on a FACScan™ flow cytometer. The
fluorescence index (FI) was calculated for each sample as:
(MF
 
sample
 
 
 
2
 
 MF
 
background
 
)/MF
 
background
 
, where MF
 
background
 
 is the
value without peptide. The percentage of residual HLA-A
 
*
 
0201
molecules was calculated by equating for each peptide the FI of
 
t
 
 
 
5
 
 2 h to 100% and then using the formula: % remaining 
 
5
 
(FI
 
t
 
5
 
n
 
/FI
 
t
 
5
 
2
 
) 
 
3
 
 100%. Because the dissociation of peptides from
MHC is a linear process, the stability of the peptide–MHC com-
plexes was measured as the time required for 50% of the mole-
cules to decay (DT
 
50
 
), starting from 
 
t
 
 
 
5
 
 2. By linear regression
analysis of the sequential measurements plotted against the per-
centage of remaining HLA-A
 
*
 
0201 molecules, the DT
 
50
 
 was cal-
culated. As a positive control, the known highly stable HBV nu-
cleocapsid 18–27 epitope was used.
In Vitro Proteasome-mediated Digestions. 20S proteasomes were
purified from a B-LCL cell line as described (57). This cell type is
known to contain immunoproteasomes (58). High LMP2 and
LMP7 content was confirmed by two-dimensional immunoblot-
ting (data not shown). To assess kinetics, digestions were per-
formed with different incubation periods. Peptides (27 mer, 20
mg) were incubated with 1 mg of purified proteasome at 378C for
1, 4, and 24 h in 300 ml proteasome digestion buffer as described
(44). TFA (30 ml) was added to stop the digestion and samples
were stored at 2208C before mass spectrometric analysis.
Mass Spectrometry. Electrospray ionization mass spectrometry
was performed on a hybrid quadrupole time of flight mass spec-
trometer, a Q-TOF (Micromass), equipped with an on-line na-
noelectrospray interface (capillary tip, 20-mm internal diameter 3
90-mm outer diameter) with an approximate flow rate of 250 nl/
min. This flow was obtained by splitting of the 0.4 ml/min flow
of a conventional high pressure gradient system, using an Acurate
flow splitter (LC Packings). Injections were done with a dedi-
cated micro/nano HPLC autosampler, the FAMOS (LC Pack-
ings), equipped with two additional valves for phase system
switching experiments. Digestion solutions were diluted five
times in water/methanol/acetic acid (95:5:1, vol/vol/vol), and 1
ml was trapped on the precolumn (MCA-300-05-C8; LC Pack-
ings) in water/methanol/acetic acid (95:5:1, vol/vol/vol). Wash-
ing of the precolumn was done for 3 min to remove the buffers
present in the digests. Subsequently, the trapped analytes were
eluted with a steep gradient going from 70% B to 90% B in 10
min, with a flow of 250 nl/min (A, water/methanol/acetic acid
[95:5:1, vol/vol/vol]; B, water/methanol/acetic acid [10:90:1,
vol/vol/vol]). This low elution rate allows for a few additional
mass spectrometry (MS)/MS experiments if necessary during the
same elution. Mass spectra were recorded from mass 50–2,000
daltons every second with a resolution of 5,000 full width/half
maximum (FWHM). The resolution allows direct determination
of the monoisotopic mass, also from multiple charged ions. In
MS/MS mode, ions were selected with a window of 2 daltons
with the first quadrupole and fragments were collected with high
efficiency with the orthogonal time of flight mass spectrometer.
The collision gas applied was argon (4 3 1025 mbar), and the col-
lision voltage z30 V. The peaks in the mass spectrum were
searched in the digested precursor peptide using the Biolynx/pro-
teins software (Micromass) supplied with the mass spectrometer.
The intensity of the peaks in the mass spectra was used to estab-
lish the relative amounts of peptides generated after proteasome
digestion. The relative amounts of the peptides are given as a per-
centage of the total amount of peptide digested by the protea-
some at the indicated incubation time.
RT-PCR Assay for PRAME Expression. Analysis of PRAME
mRNA expression was determined by RT-PCR. Total cellular
RNA was isolated with Trizol (GIBCO BRL) according to the
manufacturer’s procedure. RT reaction was performed on 5 mg
of total RNA in a reaction volume of 25 ml with 5 ml of 53 re-
verse transcriptase buffer (Promega), 2.5 ml each of 10 mM deox-
ynucleotides (Amersham Pharmacia Biotech), 0.5 mg oligo dT15
primer, 25 U of RNAsin (Promega), and 15 U avian myeloblas-
tosis virus (AMV) reverse transcriptase (Promega). The RT reac-
tion was incubated at 428C for 60 min, heat inactivated for 10
min at 708C, and diluted two times with water. For PCR ampli-
fication, 1 ml of reverse transcribed cDNA reaction mixture was
used as a template. PCR primers used for the analysis of PRAME
expression were OPC 189 (sense primer, 59-CTGTACT-
CATTTCCAGAGCCAGA-39) and OPC 190 (antisense primer,
59-TATTGAGAGGGTTTCCAAGGGGTT-39; reference 48).
PCR conditions were 5 min at 948C followed by 34 cycles con-
sisting of 30 s at 948C, 2 min at 648C, and 3 min at 728C.
In Vitro CTL Response Induction and Generation of CTL
Clones. PBMCs of two HLA-A*02011 healthy donors (one do-
nor for induction against PRA300–309 and the other donor for in-
ductions against PRA100–108, PRA142–151, PRA425–433, and PRA47–56)
were obtained by the Ficoll-Paque method and used for CTL in-76 Identification of CTL Epitopes in PRAME by Improved Epitope Prediction
ductions. To optimally use all APCs present in PBMCs, we de-
veloped a culture system that yields a mix of activated B cells and
mature DCs to be used as APCs during the primary induction
step. PBMCs were separated in a T cell fraction and a fraction
containing B cells and monocytes by SRBC rosetting. The T cell
fraction was cryopreserved. The mixture of monocytes and B cells
was cultured in 24-well plates at a concentration of 106 cells/well
in complete culture medium containing 800 U/ml GM-CSF
(provided by S. Osanto, Leiden University Medical Center), 500
U/ml IL-4 (PeproTech), and 500 ng/ml CD40 mAb (clone
B-B20; Serotec) for 6 d. This culture system achieved a threefold
effect: (a) GM-CSF and IL-4 induced differentiation of monocytes
into immature DCs (59), (b) IL-4 and CD40 mAbs caused activa-
tion and proliferation of B cells (60), and (c) CD40 mAb medi-
ated maturation of immature DCs (61). At day 3, cytokines and
CD40 mAb were replenished. To further promote CTL-inducing
capacity, the APC mix was cultured for an additional 2 d with 0.4
ng/ml LPS (Difco Labs), 500 U/ml IFN-g (Boehringer Mann-
heim), and 500 ng/ml CD40 mAb. At day 8 the APC mix was
pulsed with 50 mg/ml peptide (each peptide separately) for 4 h at
room temperature, irradiated (30 Gy), and washed to remove free
peptide. The cryopreserved autologous T cell fraction was thawed
and depleted from CD41 T cells using magnetic beads (Dynal).
The primary induction was performed in 96-well U-bottomed
plates. APCs at a concentration of 10,000/well were cocultured
with 50,000 CD81 T cells/well in culture medium containing
10% human pooled serum (HPS), 5 ng/ml IL-7 (PeproTech), and
0.1 ng/ml IL-12 (Sigma-Aldrich). At day 7 after initiation of
induction, the CTL microcultures were harvested (pooled),
washed, and restimulated at a concentration of 40,000 responder
cells/well of 96-well U-bottomed plates in culture medium con-
taining 10% HPS, 5 ng/ml IL-7, and 0.1 ng/ml IL-12. Autolo-
gous-activated B cells, generated via the protocol described by
Schultze et al. (60), irradiated (75 Gy), and peptide pulsed (50 mg/
ml) for 4 h at room temperature in culture medium containing
2% FCS and 3 mg/ml b2-microglublin (Sigma-Aldrich) after mild
acid elution to remove naturally presented peptides from the
MHC class I molecules (see Materials and Methods, MHC bind-
ing assay), were used at a concentration of 10,000 cells/well as re-
stimulator APCs. Restimulations were repeated at day 14 and 21
in a similar way, with the exception of IL-7 being replaced by 20
IU/ml IL-2 (Chiron Corp.). At day 29, the CTL bulk culture was
cloned by standard limiting dilution procedures. CTL clones were
maintained by aspecific stimulation every 7 to 12 d using a feeder
mixture consisting of allogeneic PBMCs and B-LCL in culture
medium containing 10% FCS, 1.5% leucoagglutinin (Sigma-
Aldrich), and 240 IU/ml IL-2.
51Cr Cytotoxicity Assay, HLA Class I Blocking, and Proteasome In-
hibition. CTL activity was measured in standard chromium re-
lease assays. In brief, after 51Cr labeling (1 h), target cells (2,000/
well) were added to various numbers of effector cells in a final
volume of 100 ml complete culture medium in 96-well U-bot-
tomed plates. After 4 h incubation at 378C, supernatants were har-
vested. The mean percentage of specific lysis of triplicate wells was
calculated according to: (experimental release 2 spontaneous re-
lease)/(maximal release 2 spontaneous release) 3 100%. For pep-
tide titration experiments, 51Cr-labeled target cells (2,000/well)
were pulsed with titrated amounts of peptide for 1 h at 378C in
96-well plates. Subsequently, CTLs were added at an E/T ratio of
10. HLA class I blocking was accomplished by treatment of 2 3
105 51Cr-labeled M453 melanoma cells for 1 h with mAb W6.32
or control IgG2a at room temperature before addition to effector
cells. Inhibition of proteasome function in melanoma FM3 was
performed by treatment with 10 mM of lactacystin (Calbiochem)
for 17 h during culture at 378C. Thereafter, FM3 cells were har-
vested and 51Cr labeled for use in the cytotoxicity assay. Reconsti-
tution of lysis by peptide was performed by pulsing lactacystin-
treated and 51Cr-labeled FM3 cells for 30 min with 5 mM peptide.
Results
Identification of HLA-A*0201 Binding Peptides from
PRAME. To select candidate HLA-A*0201 binding pep-
tides from PRAME, its aa sequence was screened for HLA-
A*0201 binding motif containing peptides with a combina-
tion of two known binding prediction algorithms (62, 63).
Only peptides of 9 or 10 aa length were included, taking
into account the low prevalence of HLA-A*0201–
restricted CTL epitopes of 8 or 11 aa length (64). In total,
128 peptides (65 nonamers and 63 decamers) were synthe-
sized in order to determine their actual binding affinity for
HLA-A*0201 using a competition-based cellular binding
assay (54). 19 high affinity binding peptides were identified
(IC50 # 6 mM), and 27 peptides bound with intermediate
affinity (6 mM , IC50 # 15 mM), whereas the other pep-
tides displayed a low (15 mM , IC50 # 100 mM) or unde-
tectable binding capacity (IC50 . 100 mM; Table I). To
more precisely define binding characteristics, peptide–
MHC stability was assessed by measuring the dissociation
rate of high affinity binding peptides complexed with
HLA-A*0201 at 378C (56). Two of the tested high affinity
binding peptides (PRA292–301 and PRA190–199) showed a
high off rate from HLA-A*0201, because ,10% of HLA-
A*0201–peptide complexes were detectable after 2 h incu-
bation at 378C. In previous work we have detected a strong
correlation between MHC–peptide binding stability and
immunogenicity in vivo (56). Therefore, PRA292–301 and
PRA190–199 are, with respect to their binding characteristics,
not likely to be efficiently presented in HLA-A*0201. For
all other peptides, the 50% decay time (DT50) was 2.5 h or
longer (Table II), indicating a stable association with HLA-
A*0201.
In Vitro Proteasome-mediated Digestions of 27-mer Polypep-
tides Encompassing HLA-A*0201 Binding Peptides. The
two most important requirements for a peptide to be natu-
rally presented as CTL epitope are: (a) proper excision
from the protein by the proteolytic machinery and (b) suf-
ficient binding affinity for HLA class I molecules. There-
fore, we analyzed in vitro proteasome-mediated digestions
of 27-mer polypeptides encompassing the 19 identified
high affinity HLA-A*0201 binding peptides. Potential
epitopes were primarily assessed for efficient liberation (i.e.,
by a major cleavage site at 1 h incubation) of their precise
COOH terminus, which is a first requirement for the gen-
eration of most CTL epitopes (34–37). Intactness of the
candidate epitope was evaluated as a secondary factor fa-
voring efficient processing and presentation. 20S protea-
somes isolated from a human EBV–transformed B cell line
were used for digestions with 1-, 4-, and 24-h incubation
periods, and mass spectrometry profiles of the digestion
products were analyzed. Digestion patterns of four 27-mer77 Kessler et al.
Table I. Binding Affinity for HLA-A*0201 of 128 Nonamers and Decamers Derived from PRAME
Start* Sequence Length IC50
‡ Start    Sequence Length IC50 Start    Sequence Length IC50 
300 ALYVDSLFFL 10 1.7 466 RLRELLCEL 9 14.0 86 LMKGQHLHL 9 62.3
142 SLYSFPEPEA 10 1.9 33 SLLKDEALAI 10 14.0 240 VTCTWKLPTL 10 67.2
47 LLPRELFPPL 10 2.1 422 ALQSLLQHL 9 14.2 44 ALELLPREL 9 71.3
435 NLTHVLYPV 9 2.5 103 GLDVLLAQEV 10 15.2 379 TLQDLVFDEC 10 71.9
292 FLSLQCLQAL 10 2.5 231 QLDSIEDLEV 10 15.5 371 ALLERASAT 9 72.0
394 QLLALLPSL 9 2.9 312 RLDQLLRHV 9 15.7 353 VLSLSGVMLT 10 74.6
182 FLKEGACDEL 10 3.0 493 RTFYDPEPI 9 15.8 305 SLFFLRGRL 9 79.4
294 SLQCLQALYV 10 3.2 308 FLRGRLDQL 9 16.1 409 TTLSFYGNSI 10 80.8
422 ALQSLLQHLI 10 3.2 429 HLIGLSNLT 9 16.3 93 HLETFKAVL 9 89.0
425 SLLQHLIGL 9 3.7 85 VLMKGQHLHL 10 17.0 319 HVMNPLETL 9 90.3
258 QMINLRRLLL 10 4.0 316 LLRHVMNPL 9 17.4 18 SVWTSPRRLV 10 .100
190 ELFSYLIEKV 10 4.5 353 VLSLSGVML 9 17.4 20 WTSPRRLVEL 10 .100
248 TLAKFSPYL 9 4.6 172 FIPVEVLVDL 10 17.5 26 LVELAGQSL 9 .100
39 ALAIAALEL 9 5.1 134 TVWSGNRASL 10 18.4 51 ELFPPLFMA 9 .100
100 VLDGLDVLL 9 5.2 339 VMHLSQSPSV 10 18.5 67 QTLKAMVQA 9 .100
333 RLSEGDVMHL 10 5.4 72 MVQAWPFTC 9 18.5 70 KAMVQAWPFT 10 .100
462 YLHARLREL 9 5.4 390 ITDDQLLALL 10 18.9 78 FTCLPLGVL 9 .100
360 MLTDVSPEPL 10 5.6 18 SVWTSPRRL 9 19.1 84 GVLMKGQHL 9 .100
419 SISALQSLL 9 5.7 315 QLLRHVMNPL 10 19.7 95 ETFKAVLDGL 10 .100
432 GLSNLTHVL 9 6.8 71 AMVQAWPFT 9 20.0 133 WTVWSGNRA 9 .100
214 KIFAMPMQDI 10 7.2 207 RLCCKKLKI 9 20.8 155 MTKKRKVDGL 10 .100
320 VMNPLETLSI 10 8.6 247 PTLAKFSPYL 10 21.1 165 STEAEQPFI 9 .100
39 ALAIAALELL 10 9.0 219 PMQDIKMIL 9 23.9 180 DLFLKEGAC 9 .100
390 ITDDQLLAL 9 9.2 459 RLAYLHARL 9 24.3 198 KVKRKKNVL 9 .100
242 CTWKLPTLA 9 9.3 264 RLLLSHIHA 9 24.6 205 VLRLCCKKL 9 .100
99 AVLDGLDVLL 10 9.4 217 AMPMQDIKMI 10 24.6 222 DIKMILKMV 9 .100
308 FLRGRLDQLL 10 9.6 361 LTDVSPEPL 9 26.8 224 KMILKMVQL 9 .100
355 SLSGVMLTDV 10 9.9 430 LIGLSNLTHV 10 27.2 234 SIEDLEVTC 9 .100
34 LLKDEALAI 9 10.2 33 SLLKDEALA 9 29.2 234 SIEDLEVTCT 10 .100
284 YIAQFTSQFL 10 10.4 258 QMINLRRLL 9 31.2 237 DLEVTCTWKL 10 .100
71 AMVQAWPFTC 10 10.4 91 HLHLETFKAV 10 31.8 240 VTCTWKLPT 9 .100
470 LLCELGRPSM 10 10.5 297 CLQALYVDSL 10 33.8 261 NLRRLLLSHI 10 .100
186 GACDELFSYL 10 10.6 372 LLERASATL 9 35.0 325 ETLSITNCRL 10 .100
410 TLSFYGNSI 9 11.0 401 SLSHCSQLT 9 36.9 368 PLQALLERA 9 .100
25 RLVELAGQSL 10 11.1 397 ALLPSLSHC 9 42.6 382 DLVFDECGI 9 .100
91 HLHLETFKA 9 11.1 389 GITDDQLLAL 10 47.3 382 DLVFDECGIT 10 .100
100 VLDGLDVLLA 10 11.9 417 SISISALQSL 10 48.2 383 LVFDECGIT 9 .100
454 TLHLERLAYL 10 12.2 259 MINLRRLLL 9 48.2 389 GITDDQLLA 9 .100
371 ALLERASATL 10 12.9 479 MVWLSANPC 9 49.0 401 SLSHCSQLTT 10 .100
326 TLSITNCRL 9 13.2 160 KVDGLSTEA 9 51.2 473 ELGRPSMVWL 10 .100
462 YLHARLRELL 10 13.3 436 LTHVLYPVPL 10 53.0 481 WLSANPCPHC 10 .100
350 QLSVLSLSGV 10 13.3 226 ILKMVQLDSI 10 56.1 493 RTFYDPEPIL 10 .100
99 AVLDGLDVL 9 13.4 292 FLSLQCLQA 9 58.7
*Position in PRAME of the NH2-terminal aa of the peptide. Peptides are listed in order of their IC50.
‡IC50 is peptide concentration needed to inhibit binding of FL-labeled reference peptide for 50% (IC50 in mM).78 Identification of CTL Epitopes in PRAME by Improved Epitope Prediction
polypeptides, all containing potential high affinity HLA-
A*0201 binding epitopes, are shown in Fig. 1.
Fig. 1 A shows the digestions of PRAME 90–116, which
harbors five HLA-A*0201 binding peptides (Table I) with
their natural flanking residues. Of the COOH-terminal
residues of the five HLA-A*0201 binding peptides, only
Leu-108 was generated (fragments containing this COOH
terminus added up to 8% at 1 h digestion). Therefore, both
the 9-mer VLDGLDVLL (PRA100–108) and the 10-mer
AVLDGLDVLL (PRA99–108) represent potential CTL
epitopes. The NH2 terminus of the epitope precursor is
likely to be Lys-98, because the fragments most frequently
generated were aa 90–97 and its complement aa 98–116,
indicating an abundantly cleaved site after Phe-97.
Fig. 1 B shows the digestions of 27-mer PRAME 133–
159, which contains 10-mer SLYSFPEPEA (PRA142–151),
the second best HLA-A*0201 binding peptide (Table I).
Fragments sharing Ala-151 as COOH terminus added up
to 29% at 1 h digestion, indicating an abundantly cleaved
site after this residue. Furthermore, fragment aa 142–159
and the complementary fragment aa 133–141 were abun-
dantly present, pointing to a major cleavage site after Ala-
141. Thus, major cleavage sites were present just after and
before SLYSFPEPEA, rendering this peptide a potential ef-
ficiently generated CTL epitope.
Fig. 1 C depicts digestions of PRAME 290–316 encom-
passing 10-mer ALYVDSLFFL (PRA300–309), which bound
best in HLA-A*0201 (Table I) and has its COOH terminus
(Leu-309) in common with the already described HLA-
A24–presented 9-mer LYVDSLFFL (PRA301–309; refer-
ence 48). As might be expected on that basis, a cleavage site
after Leu-309 was observed, because digestion fragments
sharing this COOH terminus were abundantly generated
after 1 h incubation. However, PRA300–309 itself was found
intact only after 24 h incubation at low quantities. This is
probably due to cleavage sites within this potential epitope
(after Val-303, Asp-304, and Leu-306). HLA-A*0201
binding peptides PRA292–301 and PRA294–303 (also in
PRAME 290–316) were, respectively, not COOH-termi-
nally generated and not found as intact fragment, indicating
that these peptides are not likely to be naturally generated
in the processing pathway.
Fig. 1 D shows the digestion pattern of PRAME 415–
441, which harbors four peptides binding in HLA-A*0201
(Table I). The NH2-terminally elongated decameric pre-
cursor 424QSLLQHLIGL433 of high affinity binding 9-mer
SLLQHLIGL (PRA425–433) was efficiently generated. The
abundant generation of the COOH-terminal and NH2-
terminal counterparts of this 10-mer precursor (fragments
aa 434–441 and aa 415–423, respectively) were also point-
ing to major cleavage sites just after and before
424QSLLQHLIGL433, indicating PRA425–433, a potential
CTL epitope. The three other HLA-A*0201 binding pep-
tides were either not COOH-terminally excised (PRA419–427
and PRA422–430) or the correct COOH terminus was found
only after 4 h incubation (PRA422–431).
A concise representation of digestion analysis of 27-mers
harboring all 19 high affinity binding peptides, including
those discussed above, is shown in Fig. 2. Summarizing, 11
HLA-A*0201 binding peptides were either not COOH-
terminally excised (PRA47–56, PRA435–443, PRA292–301,
PRA182–191, PRA248–256, PRA100–108, and PRA360–369) or the
correct COOH terminus was generated only after 4 h in-
cubation by a minor cleavage site (PRA394–402, PRA422–431,
PRA190–199, and PRA419–427). The absence or late appear-
ance of fragments containing the correct COOH terminus
render these 11 peptides very unlikely to constitute natu-
rally processed epitopes. Furthermore, three peptides were
COOH-terminally liberated at 1 h digestion but only in
very low quantities (,1%, data not shown; PRA258–267,
PRA333–342, and PRA462–470), whereas PRA294–303 was not
found as intact fragment. Consequently, it is doubtful that
the latter peptides are efficiently generated in vivo. Only
the high affinity binding peptides PRA100–108, PRA142–151,
PRA300–309, and PRA425–433 were COOH-terminally ex-
cised by a major cleavage site at 1 h incubation and found
intact in digestion fragments, indicating possible CTL
epitopes (Figs. 1 and 2). Therefore, these four peptides
were chosen for CTL inductions.
In Vitro Human CTL Inductions against Four Putative
HLA-A*0201–restricted Epitopes. Separate CTL induc-
tions, using PBMCs of healthy donors, were performed
against VLDGLDVLL (PRA100–108), SLYSFPEPEA
Table II. Stability of High Affinity Binding Peptides in
HLA-A*0201
Start* Sequence‡
Affinity
IC50
§
Stability
DT50
i
mMh
300 ALYVDSLFFL 1.7 .4
142 SLYSFPEPEA 1.9 3
47 LLPRELFPPL 2.1 2.5
435 NLTHVLYPV 2.5 3
292 FLSLQCLQAL 2.5 N.S.¶
394 QLLALLPSL 2.9 .4
182 FLKEGACDEL 3.0 3
294 SLQCLQALYV 3.2 .4
422 ALQSLLQHLI 3.2 2.5
425 SLLQHLIGL 3.7 .4
258 QMINLRRLLL 4.0 .4
190 ELFSYLIEKV 4.5 N.S.
248 TLAKFSPYL 4.6 .4
100 VLDGLDVLL 5.2 2.5
HBV control** .4
*Start aa position of peptide in PRAME.
‡In addition to all high affinity binding peptides, PRAME 100–108 and
371–380 are tested.
§Binding affinity expressed as IC50 (see Table I).
iDT50 is given starting from t 5 2 h at 378C.
¶N.S., not stable; ,10% of HLA molecules detectable after 2 h incuba-
tion at 378C.
**HBV nucleocapsid 18–27 is used as control peptide.79 Kessler et al.
(PRA142–151), ALYVDSLFFL (PRA300–309), and SLLQH-
LIGL (PRA425–433) according to the protocol described in
Materials and Methods. At day 28, the CTL bulk cultures
were tested in a 51Cr release assay to asses peptide specific-
ity. The CTL cultures raised against SLYSFPEPEA and
SLLQHLIGL showed high specificity for targets loaded
with the inducing peptide (at an E/T ratio of 5, both cul-
tures reached 80% lysis compared with 20% lysis of targets
loaded with a control peptide), whereas the other two CTL
cultures  displayed only slightly increased lysis of targets
loaded with the relevant peptide (data not shown). The
four CTL bulk cultures were cloned by limiting dilution at
day 29. The peptide specificity of generated CTL clones
was initially assessed in a split-well cytotoxicity assay. De-
spite low peptide specificity of CTL bulk cultures against
VLDGLDVLL and ALYVDSLFFL, CTL clones specific for
Figure 1. In vitro  protea-
some-mediated digestions of
four 27-mer PRAME polypep-
tides containing potential HLA-
A*0201–restricted epitopes.  20S
proteasomes isolated from an
EBV-transformed B cell line
were coincubated with 27-mer
PRAME peptides at 378C for
the indicated time points. Diges-
tion mixtures were analyzed by
mass spectrometry as described in
Materials and Methods. Gener-
ated digestions fragments are de-
picted as shaded sequences. The
digestion of 27-mer PRAME
90–116 is represented in A, di-
gestion of PRAME 133–159 is
depicted in B, in C the digestion
of PRAME 290–316 is showed,
and D represents the digestion of
PRAME 415–441. Notes: (1)
IC50 as determined in competi-
tion binding assay (see Table I);
(2) peptides binding with high or
intermediate affinity to HLA-
A*0201 are shown. Predicted
epitopes used for CTL induction
are printed in bold; (3) digestion
fragments are shaded and or-
dered according to their COOH
terminus; (4) digestion fragments
generated for ,1% at 1 h diges-
tion or ,3% at 4 and 24 h incu-
bation and not relevant for
epitope prediction are not
shown; (5) intensity is expressed
as percentage of total summed
mass-peak intensities of digested
27-mer at the indicated incuba-
tion time.80 Identification of CTL Epitopes in PRAME by Improved Epitope Prediction
all four peptides were found. In summary, 51 of 576 (9%)
CTL clones induced against VLDGLDVLL (PRA100–108)
showed specific lysis of peptide pulsed targets and 19 of 202
(9%) CTL clones raised against ALYVDSLFFL (PRA300–309)
displayed peptide specificity. As may be expected, higher
percentages, namely 92% (279 of 304), of clones against
SLYSFPEPEA (PRA142–151) and 29% (97 of 336) of clones
against SLLQHLIGL (PRA425–433) showed peptide specific-
ity. Based on peptide reactivity and growth characteristics,
several CTL clones were functionally characterized in de-
tail. For each specificity, one CTL clone is presented in this
study. As shown in Fig. 3 A, representative CTL clones
raised against the four different peptides all showed highly
specific and efficient lysis of T2 cells pulsed with 5 mM of
their inducing peptides at low E/T ratios. Peptide sensitiv-
ity of the CTL clones was determined in peptide titration
experiments (Fig. 3 B). CTL no. 551 (anti-PRA100–108) was
able to half-maximally lyse targets loaded with VLDGLD-
Figure 2. Proteasome-mediated cleavage patterns of 27-mer peptides encompassing 19 high affinity HLA-A*0201 binding PRAME peptides. 20S pro-
teasomes isolated from an EBV-transformed B cell line were coincubated with 27-mer PRAME peptides at 378C for the indicated time points. Digestion
mixtures were analyzed by mass spectrometry as described in Materials and Methods. Major and minor cleavages sites at 1 h digestion are depicted. Notes:
(1) all 19 high affinity binding peptides (IC50 , 6 mM) are listed and ranked according to their binding affinity for HLA-A*0201; (2) start aa position in
PRAME of the HLA-A*0201 binding peptide. (3) IC50 (in mM) as determined in competition binding assay (see Table I); (4) start and end aa position in
PRAME of 27-mer polypeptide encompassing the high affinity binding peptide; (5) aa sequence of 27-mer polypeptide (aa sequence of HLA-A*0201
binding peptide is printed in bold and shaded); (6) major (bold arrows) and minor (thin arrows) cleavage sites at 1 h incubation are depicted, classified ac-
cording to the following definitions. Major site: fragments containing as COOH terminus the residue NH2-terminal from the cleavage are present for
$5% at 1 h incubation. Minor site: fragments containing as COOH terminus the residue NH2-terminal from the cleavage are present for ,5% at 1 h
incubation. (7) Generation by digestion of fragments containing the correct COOH terminus of the HLA-A*0201 binding peptide. Generation at 1 h di-
gestion or after a longer incubation period is separately indicated. Classification: (11) present for $5%, (1) present for ,5%, (2) no fragments contain-
ing the correct COOH terminus were found. (8) Generation by digestion of fragments containing the intact HLA-A*0201 binding peptide and/or NH2-
terminal elongated precursors of the peptide. Classification: (11) present for $5% at 1 h incubation, (1) present for ,5% at 1 h or only detectable after 4 or
24 h, (2) no fragments containing the HLA-A*0201 binding peptide were found. (9) Epitope prediction based on digestion results. Classification: (1)
most likely an epitope, (1/2) doubtful epitope, (2) not an epitope.81 Kessler et al.
VLL at z5 nM peptide. CTL no. 314, raised against SLYS-
FPEPEA (PRA142–151), lysed T2 cells at half-maximal level
when pulsed with ,1 nM of the inducing peptide. CTL
no. 460 (anti-PRA300–309) was extremely sensitive in lysing
T2 cells pulsed with ALYVDSLFFL: half-maximal lysis was
reached at z3 pM peptide concentration. Finally, CTL no.
1257 (anti-PRA425–433) was able to half-maximally lyse tar-
gets loaded with SLLQHLIGL at ,12 nM. To analyze
clonality of the CTL clones under investigation, we per-
formed RT-PCR analysis with a panel of 24 primers of
junctional regions of TCRB transcripts from 22 well-estab-
lished TCRBV families to determine Vb usage of the TCR
(65). All CTL clones were shown to use a single Vb, con-
firming clonality of the clones (data not shown).
Figure 3. HLA-A*0201–
restricted peptide specificity and
sensitivity of CTL clones raised
against four PRAME peptides.
(A) Lysis by CTL clones no.
551 anti-PRA100–108, no. 314
anti-PRA142–151, no. 460 anti-
PRA300–309, and no. 1257 anti-
PRA425–433 of 51Cr-labeled T2
cells loaded with 5 mM of the
relevant peptide (m) vs. an irrel-
evant HLA-A*0201 binding
peptide (d) at different E/T ra-
tios ranging from 50 to 0.75. (B)
Lysis by the same set of CTL
clones of 51Cr-labeled T2 cells
pulsed for 1 h with titrated con-
centrations of relevant peptide
(m). The CTL clones were used
at an E/T ratio of 10. Results of
one representative experiment
out of three performed are
shown.
Figure 4. Recognition by
CTL clones of four endoge-
nously processed PRAME
epitopes presented on mela-
noma cell lines in an HLA class
I–restricted and proteasome-
dependent fashion.  (Top) Lysis
of 51Cr-labeled melanoma cell
line Mel603, expressing PRAME
but lacking HLA-A*0201 ex-
pression (d), was tested vs. lysis
of M453 (j) and FM3 (m), both
expressing PRAME and HLA-
A*0201 together. CTL clones
no. 551 anti-PRA100–108, no. 314
anti-PRA142–151, no. 460 anti-
PRA300–309, and no. 1257 anti-
PRA425–433 were used at E/T ra-
tios ranging from 25 to 0.75.
(Middle) Lysis of 51Cr-labeled
M453 was tested after 1 h prein-
cubation with HLA class I
blocking mAb W6.32 (black
bars) or an IgG2a control Ab
(gray bars). (Bottom) Lysis of
51Cr-labeled FM3 was tested af-
ter 17 h treatment with 10 mM
of the proteasome inhibitor lac-
tacystin (black bars) or without
treatment (gray bars). As control,
the lactacystin-treated cells were
loaded with the relevant peptide
(white bars). Results of one rep-
resentative experiment of at least
three performed are shown.82 Identification of CTL Epitopes in PRAME by Improved Epitope Prediction
CTLs Raised against Four PRAME Peptides Recognize Mel-
anoma Cell Lines Coexpressing HLA-A*0201 and PRAME in
an HLA I–restricted and Proteasome-dependent Fashion.
Endogenous presentation of the candidate epitopes
PRA100–108, PRA142–151, PRA300–309, and PRA425–433 in
HLA-A*0201 was explored by assessing the ability of CTL
clones that were raised against these peptides to specifically
lyse melanoma cell lines M453 and FM3 expressing HLA-
A*0201 (confirmed by flow cytometry, data not shown)
and PRAME (determined by Northern blotting, data not
shown). Both melanoma cell lines were efficiently lysed by
all four CTL clones as measured in a 51Cr release assay,
whereas the melanoma Mel603 expressing PRAME (as-
sayed with RT-PCR, data not shown) but lacking HLA-
A*0201 was not killed above background level (Fig. 4, top
panel). Lysis of M453 was significantly inhibited after treat-
ment of this target with HLA class I blocking mAb W6.32
(Fig. 4, middle panel), indicating that killing of M453 by
these CTL clones involved HLA class I–restricted recogni-
tion. Furthermore, proteasome inhibition experiments with
lactacystin were performed. Lysis of FM3 pretreated for
17 h with lactacystin (10 mM) was significantly diminished
(Fig. 4, bottom panel). This indicated, in concordance with
our in vitro proteasome digestion data, that generation of
the four epitopes is proteasome dependent. To confirm
PRAME as source of antigen naturally presented in HLA-
A*0201, renal cell carcinoma cell line MZ1851, which
is HLA-*02011 but lacks PRAME expression, was
transfected with full-length PRAME cDNA (MZ1851-
PRAME). As shown in Fig. 5, PRAME expression (con-
firmed by RT-PCR) sensitized MZ1851-PRAME for lysis
by a CTL clone directed against PRA300–309.
CTLs Reactive with Four PRAME Epitopes Lyse a Broad
Array of Tumor Cell Lines Expressing HLA-A*0201 and
PRAME. To investigate HLA-A*0201–restricted presen-
tation of PRA100–108, PRA142–151, PRA300–309, and PRA425–433
on tumor cells from histologic origins other than mela-
noma, we used panels of cell lines derived from various tu-
Figure 5. Lysis of PRAME transfected renal cell carcinoma cell line
MZ1851 by CTL anti-PRA300–309.  CTL no. 460 directed against
PRA300–309 was tested on 51Cr-labeled MZ1851 (HLA-A*02011 but lack-
ing PRAME expression) transfected with PRAME cDNA (m) vs.
MZ1851 transfected with the empty vector (d). CTL no. 460 was used
at E/T ratios ranging from 50 to 0.75. Results of one representative ex-
periment of three performed are shown.
Figure 6. Lysis of tumor cell
lines from multiple histologic or-
igins by CTL anti-PRAME in a
PRAME-specific and HLA-
A*0201–restricted fashion. (Top)
Lysis of 51Cr-labeled renal cell
carcinoma cell lines MZ1851,
expressing HLA-A*0201 but
PRAME negative (d), MZ1257
(PRAME1 and HLA-A*02011)
(j), and MZ1774 (PRAME1
and HLA-A*02011) (m) was
compared. (Middle) Lysis of
51Cr-labeled lung carcinoma cell
lines. GLC02, expressing
PRAME but HLA-A*0201 neg-
ative (d) and GLC36 (m) ex-
pressing both PRAME and
HLA-A*0201 was compared.
(Bottom) 51Cr-labeled mam-
mary carcinoma cell lines MCF7
(HLA-*02011 and PRAME1)
(d) and ZR-75-1, expressing
PRAME but lacking HLA-
A*0201 (m), were tested.
The CTL clones no. 551
anti-PRA100–108, no. 314 anti-
PRA142–151, no. 460 anti-
PRA300–309, and no. 1257
anti-PRA425–433 were used at
E/T ratios ranging from 25 to
0.75. Results of one representa-
tive experiment of at least three
performed are shown.83 Kessler et al.
mor types which have been reported to express PRAME
(48, 50).
Lysis by the selected CTL clones of tumor cell lines with
or without HLA-A*0201 expression and naturally express-
ing PRAME or lacking PRAME expression was com-
pared. HLA-A*0201 expression was confirmed by flow
cytometry (data not shown) and PRAME expression by
RT-PCR or Northern blotting (data not shown). Lysis of
the HLA-A*02011 renal cell carcinoma (RCC) cell line
MZ1851, which lacks PRAME expression, was compared
with lysis of RCC cell lines MZ1257 and MZ1774, both
expressing HLA-A*0201 and PRAME. The CTL clones
reactive against the four different PRAME peptides
showed significant lysis of the two PRAME1 cell lines but
not of MZ1851, again confirming PRAME as the source of
target antigens (Fig. 6, top panel). Likewise, lysis of lung
carcinoma cell lines was HLA-A*0201 restricted and
PRAME specific, because only GLC36 expressing HLA-
A*02011 and PRAME1, and not GLC02, which is
PRAME1 but lacks HLA-A*0201 expression, was killed
(Fig. 6, middle panel). Mammary carcinoma cell line
MCF7 (HLA-A*02011 and PRAME1) was killed effi-
ciently as well, whereas cell line ZR-75-1, which lacks
HLA-A*0201 but expresses PRAME, was not lysed above
background level (Fig. 6, bottom panel). Finally, HPV161
cervix carcinoma cell line C33 and osteosarcoma cell line
SAOS, both HLA-A*02011 and PRAME1, were effi-
ciently killed by the CTL clones (data not shown), under-
scoring the broad expression pattern of the PRAME
epitopes by tumors. Taken together, we observed a consis-
tent lysis of tumor cell lines when both the relevant MHC
molecule and the tumor Ag were expressed. These re-
sults indicate that PRA100–108, PRA142–151, PRA300–309, and
PRA425–433 are presented by HLA-A*0201 on a broad array
of tumor cell lines.
CTL Clones Recognizing a Nonprocessed High Affinity Bind-
ing Peptide Do Not Lyse PRAME and HLA-A*0201–express-
ing Tumor Cell Lines. To further validate our epitope pre-
diction procedure and investigate possible false negative
epitope prediction, CTLs were induced against the highest
affinity HLA-A*0201 binding peptide that was not gener-
ated in vitro by proteasome-mediated breakdown: LL-
PRELFPPL (PRA47–56; Table I and Fig. 2). Digestion of
the 27-mer PRAME 37–63 showed that the COOH ter-
minus of LLPRELFPPL was not generated. Instead, cleav-
age sites were observed after Leu-45, Met-58, and Ala-59
(Fig. 2). Dual cleavage fragments 46ELLPRELFPPLFM58
and  46ELLPRELFPPLFMA59 were abundantly found at 1 h
digestion (data not shown). Using the same induction pro-
tocol as used for the four identified epitopes, CTLs were
generated against LLPRELFPPL. Three CTL clones recog-
nizing this peptide with high affinity were tested for lysis of
PRAME and HLA-A*0201–expressing tumor cell lines at
different E/T ratios (Table III). For comparison, three CTL
clones recognizing the SLYSFPEPEA epitope (PRA142–151)
with equal affinity as the affinity of CTL anti-PRA47–56 for
LLPRELFPPL were included in the same experiment. The
results show that CTLs raised against LLPRELFPPL do not
lyse any of the tumor cell lines, whereas the same targets
were efficiently killed by the control CTLs directed against
SLYSFPEPEA (Table III). These data strongly suggest that
LLPRELFPPL is not endogenously generated, supporting
the accuracy of our epitope prediction procedure and the
relevance of the proteasome digestion analysis. In addition
to these data, high affinity CTL clones generated against
three different BCR-ABL fusion protein–derived peptides
failed to recognize BCR-ABL–expressing target cells (data
not shown). Subsequent analysis of in vitro processing of
these peptides showed that the proteasome did not generate
the COOH terminus of any of these high affinity HLA
class I binding peptides. These results confirm the impor-
tance of proper proteasomal cleavage for the generation of
HLA class I–presented epitopes.
Table III. Percent Specific Lysis of PRAME- and
HLA-A*0201–Expressing Tumor Cell Lines by CTL Clones 
Specific for LLPRELFPPL (Not Processed) and SLYSFPEPEA 
(Processed) as Determined in a 51Cr Cytotoxicity Assay
CTL clones
anti-LLPRELFPPL
CTL clones
anti-SLYSFPEPEA
Tumor
cell line*
E/T
ratio No. 3 No. 61 No. 120 No. 314 No. 343 No. 509
M453 6 2 2 10 33 39 26
3 33 1 12 63 21 6
1, 5 1 2 9 27 17 15
MZ1257 6 1 9 0 52 28 27
3 1 8 4 34 16 26
1, 5 2 8 2 32 12 12
MZ1774 6 7 8 10 43 42 31
3 89 1 03 32 51 6
1, 5 4 4 8 21 13 10
GLC36 6 2 10 7 26 28 18
3 7 11 9 30 22 17
1, 5 5 9 7 21 20 16
MCF7 6 5 8 7 56 26 32
3 6 9 7 52 24 19
1, 5 4 9 5 48 21 13
CTL
sensitivity‡ 0.1–1 0.1–1 0.1–1 0.1–1 0.1–1 0.1–1
*Cell lines used as targets are derived from melanoma (M453), renal
cell cancer (MZ1257 and MZ1774), lung cancer (GLC36), and mam-
mary cancer (MCF7).
‡CTL sensitivity for peptide expressed as [peptide] in nM at which the
indicated CTL clone half-maximally lysed T2 cells pulsed with titrated
amounts of peptide.84 Identification of CTL Epitopes in PRAME by Improved Epitope Prediction
Discussion
In a systematic search for new CTL epitopes in known
protein sequences with tumor restricted expression, the
strategy of in vitro stimulation of CTLs with predicted
epitopes (also coined “reverse immunology”) has success-
fully led to the identification of several epitopes (18–25),
but has met with many failures and is generally inefficient
(our unpublished results and references 26–30). The current
study reports the identification of four novel HLA-A*0201–
restricted CTL epitopes in PRAME (PRA100–108, PRA142–151,
PRA300–309, and PRA425–433) by an improved multistep
epitope prediction procedure. Using in vitro proteasome-
mediated digestion pattern analysis, the four epitopes were
chosen for CTL inductions and shown to be naturally pre-
sented. In addition, we show that CTL clones with high
sensitivity for high affinity binding peptide PRA47–56, which
was not produced in vitro by proteasome-mediated diges-
tion (Fig. 2), were unable to lyse PRAME and HLA-
A*0201–expressing tumor cell lines (Table III), indicating a
lack of endogenous processing of this peptide. Taken to-
gether, both findings imply the accuracy and relevance of
the proteasome-mediated digestion pattern analysis.
Importantly, only 4 out of the 19 peptides (PRA100–108,
PRA142–151, PRA300–309, and PRA425–433) were COOH-ter-
minally excised by a major cleavage site at 1 h incubation
and were contained intact in digestion fragments as well,
indicating possible abundantly expressed CTL epitopes.
This reduction to 21% of high affinity HLA-A*0201 bind-
ing peptides being efficiently processed, which is in con-
cordance with an estimation by Yewdell et al. (66), permit-
ted us to avoid laborious and time consuming CTL
inductions against unlikely epitopes. Indeed, the four pre-
dicted epitopes were all shown to be endogenously pro-
cessed and presented (Figs. 4–6). For future epitope predic-
tions in other proteins, it will be worthwhile to first
systematically characterize proteasome digestion patterns of
a complete set of overlapping long (e.g., 30-mer) polypep-
tides and subsequently determine binding affinities for
MHC class I molecules of interest of only those peptides
that are shown to be COOH-terminally excised by a major
cleavage site. This experimental order reflects the physio-
logical sequence of events, with the primacy of CTL
epitope generation at antigen processing and not at MHC
binding as indeed has been observed for MHC II epitope
presentation (67).
Possibly, in the future, reliable proteasome cleavage pre-
diction algorithms will allow by-passing of experimental
digestions. Efforts to develop such algorithms have been re-
ported (68, 69). By prediction algorithms of Kuttler et al.
(69), three of the four epitopes identified in our study
(PRA142–151, PRA300–309, and PRA425–433) were predicted to
be correctly COOH-terminally liberated. In contrast, the
COOH terminus of PRA100–108, which is generated by a
major cleavage site in our study, was not predicted. Of the
25 major cleavage sites observed (Fig. 2), 17 sites (68%)
were correctly predicted by the most optimal algorithm
variant (type II) as well as 10 of the 23 (43%) minor cleav-
age sites observed at 1 h digestion (by algorithm variant
type III). Furthermore, many cleavage sites were falsely
predicted by the algorithms, including erroneous internal
epitope destruction sites, thus reducing the value of the
current algorithms. Although these differences may be
partly attributable to the different types of proteasomes
used (immunoproteasomes in this study versus constitutive
proteasomes in reference 69), we conclude that this first ac-
cessible proteasome cleavage prediction algorithm is not yet
accurate enough to be used without experimental verifica-
tion. As suggested by Kuttler et al. (69), a further enlarge-
ment of the training data used to educate the algorithm is
likely to improve the accuracy of prediction.
With respect to the utilization and interpretation of pro-
teasome-mediated digestion patterns for epitope prediction
as reported here, several points must be raised. For protea-
some-mediated digestions, we used 20S proteasomes iso-
lated from an EBV-transformed B cell line known to con-
tain mainly so-called immunoproteasomes with LMP2,
LMP7, and MECL1 subunits (58). This implies that the
four identified epitopes are likely to be presented on full-
length PRAME expressing mature DCs containing immu-
noproteasomes next to their expression on tumor cells
(containing constitutive proteasomes). For whole antigen
vaccine development, such epitopes are favorable in con-
trast to a type of CTL epitope of which the presentation
has been reported to be abrogated in mature DCs (70). The
reported reverse effect, an inefficient processing in cells
containing constitutive proteasomes (71–74), is excluded
for our CTL epitopes by the functional data (Figs. 4–6).
The selection of candidate epitopes was mainly based on
generation of the correct COOH terminus by an early ma-
jor cleavage site, which is considered a sine qua none for
efficient epitope generation (34–37). Late emergence (at 4
or 24 h) of the correct COOH terminus or generation by a
minor cleavage site is not expected to yield epitopes or
only at very low density, respectively. In contrast, cleavage
sites within the epitope were less heavily weighed in the
epitope prediction. In particular, ALYVDSLFFL (PRA300–309)
was found to be cleaved at several sites within the epitope
(Fig. 1 C). Although this phenomenon does not exclude
epitope formation, as reported for epitopes of murine leu-
kemia virus and CMV (37, 75), partial destruction of an
epitope can severely hamper its efficient presentation (for a
review by Niedermann et al., see reference 76). Despite
that, the PRA300–309 peptide was included in our CTL in-
ductions for several reasons: (a) generation of its COOH
terminus by a major cleavage site (Fig. 1 C), (b) reported
presentation of the 9-mer length variant PRA301–309 (LY-
VDSLFFL) in HLA-A24 (48), and (c) favorable binding ca-
pacity (Table I). Furthermore, (d) it can not be excluded
that in vitro digestions are prone to a “recharging-effect”:
longer epitope precursor fragments (containing the correct
COOH terminus) can be further degraded by reentry in
the proteasome, a phenomenon which will presumably not
occur in vivo, because translocation of polypeptides by85 Kessler et al.
TAP to the ER has been shown to occur as soon as 15 min
after protein synthesis (and consequently proteasome diges-
tion [77]). However, our control experiments did not re-
veal a significant effect of peptide substrate concentration
on the relative digestion fragment kinetics (data not
shown), making pronounced effects of recharging unlikely
and indicating that the observed kinetics at least partially
reflect the primary cleavage pattern and fragment abun-
dancy. Finally, (e) cleavage within this epitope may be di-
minished when digested with constitutive proteasomes in-
stead of immunoproteasomes, as enhanced cleavages after
leucine and valine (hydrophobic residues) by the latter type
of proteasomes have been described (76).
Our data support the current notion that a significant
proportion of CTL epitopes is produced by the proteasome
as NH2-terminally extended precursor (36, 38–41). Diges-
tion analysis of PRAME 415–441 revealed that 9-mer
PRA425–433 is abundantly generated as NH2-terminally
elongated 10-mer 424QSLLQHLIGL433 (Fig. 1 D), render-
ing it likely that this fragment is translocated by TAP to
the ER and is trimmed there to its final length. Likewise,
9-mer PRA100–108 is presumably formed as 11-mer
98KAVLDGLDVLL108, which also indicates that the inter-
mediate binding 10-mer PRA99–108 may be presented as
well (Fig. 1 A). In contrast, SLYSFPEPEA (PRA142–151) is
likely available for TAP translocation in its precise length,
because this peptide was found in significant quantities as
digestion fragment at 1 h digestion (Fig. 1 B). This is in
concordance with a recent report showing that the protea-
some can generate both COOH and NH2 termini of some
epitopes (78).
PRAME is a particularly attractive tumor-associated an-
tigen because it is widely expressed in many different tu-
mor types (48–51), but not in normal tissues, except testis,
and at very low levels in endometrium, ovaries, and
adrenals (48). Indeed, CTL clones recognizing the four
novel HLA-A*0201–restricted PRAME epitopes specifi-
cally lysed melanoma, renal cell, lung, mammary, and cer-
vical carcinoma cell lines (Figs. 4 and 6). Therefore, and
given the high prevalence of HLA-A*0201 among the
Caucasian population, these epitopes are expected to be
applicable for immunotherapeutic purposes (adoptive CTL
therapy, vaccine design, and/or immunomonitoring) in a
high percentage of cancer patients. Undesirable autoim-
mune CTL reactivity against the few tissues expressing
PRAME at low levels is not to be expected, because ex-
pression levels are most likely too low to ensure CTL rec-
ognition as shown in vitro with human MAGE-specific
CTLs by Lethe et al. (79) and in vivo in a murine p53
model by our group (80). Nevertheless, control recogni-
tion studies with normal endometrium, ovary, or adrenal
tissues should ascertain absence of harmful responses to-
wards healthy tissues expressing PRAME at low levels (ex-
pression level ,3–5% of that found in melanoma, with the
exception of endometrium, which expresses up to 30% of
the melanoma level [48]). So far we have been unable to
establish sufficient primary cell cultures of those sources for
functional analysis.
Although not the principle objective of this study, we
found a remarkable immunogenicity in healthy donors of
the four epitopes, because CTL inductions against the four
peptides (performed with blood of two separate donors, see
Materials and Methods) were all successful. Particularly,
PRA142–151 and PRA425–433 vigorously induced CTL bulk
cultures recognizing these peptides as endogenously ex-
pressed PRAME epitopes. Apparently, the low level ex-
pression of PRAME in some healthy tissues did not induce
irreversible tolerance against the four identified epitopes.
Future comparison of CTL frequencies in healthy donors
versus cancer patients, as determined by, e.g., tetramer
studies or enzyme-linked immunospot analysis, will reveal
whether cancer patients are naturally primed against the
four epitopes. Furthermore, such experiments may allow
an immunodominance ranking of the epitopes. Our diges-
tion data suggest a ranking in efficiencies of proteasome-
mediated generation of the four epitopes, which is a major
factor determining immunodominance (66, 76). Because of
the higher abundance of epitope precursor fragments and
absence of major cleavage sites within the epitopes,
PRA142–151 and PRA425–433 are probably more efficiently
generated than PRA100–108 and PRA300–309 (Figs. 1 and 2).
Finally, we expect that our novel epitope prediction
methodology will help to rapidly identify PRAME-derived
CTL epitopes presented in HLA class I molecules other
than HLA-A*0201 and will boost the reverse immunology
approach for other tumor specific proteins as well. Such a
systematic identification of new CTL epitopes in different
tumor antigens will allow the development of multiantigen
(epitope-based) tumor vaccines, covering all HLA class I
haplotypes, which is probably needed to circumvent tumor
escape by antigen loss variants.
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